长药控股(300391) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥545,854,075.80, representing a 26.71% increase compared to the same period last year[5] - The net profit attributable to shareholders was -¥91,637,332.76, a decrease of 235.36% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥91,457,611.31, down 235.56% from the previous year[5] - The company reported a 28.17% decrease in operating income year-on-year, primarily due to reduced sales in the pharmaceutical sector[8] - Total operating revenue for Q3 2023 was CNY 1,021,867,556.56, a decrease of 28.2% compared to CNY 1,422,647,907.32 in the same period last year[15] - Net loss for Q3 2023 amounted to CNY -137,591,259.61, compared to a net profit of CNY 103,109,145.51 in Q3 2022[16] - The company reported a significant increase in credit impairment losses, totaling CNY -102,547,563.34, compared to CNY -43,884,447.21 in the previous year[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,742,686,088.11, an increase of 4.59% compared to the end of the previous year[5] - The total assets as of Q3 2023 were CNY 3,742,686,088.11, an increase from CNY 3,578,587,920.62 at the end of the previous year[15] - Total liabilities increased to CNY 2,155,621,412.54 from CNY 1,913,967,101.32 year-on-year[15] - The company's total liabilities increased significantly, with accounts payable rising by 44.16% to ¥283,418,697.25 due to increased material payables in the pharmaceutical sector[8] - The company's goodwill stood at CNY 619,510,988.35, down from CNY 675,429,707.61 in the previous year[15] - The total equity attributable to shareholders of the parent company decreased to CNY 684,820,331.69 from CNY 800,672,725.91 year-on-year[15] Cash Flow - The cash flow from operating activities for the year-to-date was ¥31,937,006.16, showing a significant increase of 133.30%[5] - Cash flow from operating activities generated a net cash inflow of 31,937,006.16, a significant improvement from a net outflow of -95,920,024.49 in the same period last year[18] - Total cash inflow from financing activities was 111,786,645.33, while cash outflow was 146,676,641.29, resulting in a net cash outflow of -34,889,995.96[18] - Cash and cash equivalents at the end of the period stood at 6,568,862.86, compared to 3,959,644.33 at the end of the previous period[18] - The company reported a cash inflow of 229,522,228.74 from other operating activities, significantly higher than 66,617,775.71 in the previous period[17] - The company received 8,322,333.68 in tax refunds, slightly up from 7,154,191.53 in the previous period[17] Shareholder Information - As of September 30, 2023, the total number of common shareholders was 17,335[10] - The company reported a total of 35,423,600 shares held by its largest shareholder, accounting for 10.11% of total shares[10] - The largest shareholder, Changxing Shengshi Fenghua Business Co., Ltd., has pledged 26,781,700 shares[10] Other Financial Metrics - The company's basic and diluted earnings per share were both -¥0.2616, reflecting a decrease of 235.40% year-on-year[5] - Basic and diluted earnings per share for the third quarter were -0.3307, compared to 0.0783 in the previous period[17] - Research and development expenses for Q3 2023 were CNY 6,136,499.43, significantly lower than CNY 20,299,073.15 in the same period last year[15] - The company reported a significant increase in financial expenses, totaling CNY 57,380,083.49, compared to CNY 36,152,529.71 in Q3 2022[15] Operational Changes - The company experienced a 510.85% increase in asset impairment losses, attributed to provisions for inventory depreciation and fixed asset impairment[8] - The company recorded a significant increase in other income, which rose by 886.00% to ¥81,282,206.95, mainly due to unfulfilled commitments from a major asset restructuring[8] - The company has not disclosed any new product developments or market expansion strategies in the report[12] - There were no significant changes in the status of restricted shares during the reporting period[12] Reporting and Audit - The company has not yet audited the third quarter report[19] - The report was released by the board of directors on October 25, 2023[20]